Early interventions in risk groups for schizophrenia: What are we waiting for?

npj Schizophrenia

Volumn 2, Issue , 2016, Pages

  Sommer, Iris E ^a   Bearden, Carrie E ^b   Van Dellen, Edwin ^a   Breetvelt, Elemi J ^a   Duijff, Sasja N ^a   Maijer, Kim ^a   Van Amelsvoort, Therese ^c   De Haan, Lieuwe ^d   Gur, Raquel E ^e   Arango, Celso ^f   Díaz Caneja, Covadonga M ^f   Vinkers, Christiaan H ^a   Vorstman, Jacob A S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; CHOLINE; OXIDIZING AGENT;

ARTICLE; BRAIN MATURATION; BULLYING; CHROMOSOME DELETION 22Q11; COGNITIVE DEFECT; COGNITIVE DEVELOPMENT; DISEASE COURSE; DRUG ABUSE; EARLY INTERVENTION; ECONOMIC ASPECT; EXERCISE; FIRST DEGREE RELATIVE; GENETIC RISK; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; MENTAL DISEASE; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL ADAPTATION; SOCIAL EVOLUTION; SOCIAL EXCLUSION; STRESS;

EID: 85012002213     PISSN: None     EISSN: 2334265X     Source Type: Journal    
DOI: 10.1038/npjschz.2016.3     Document Type: Article

References (119)

1. McGrath, J., Saha, S., Chant, D. & Welham, J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 30, 67-76 (2008).
2. Gustavsson, A. et al. Cost of disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21, 718-779 (2011).
3. Buchanan, R. W. et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 36, 71-93 (2010).
4. Dixon, L. B. et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr. Bull. 36, 48-70 (2010).
5. Harvey, P. D. Disability in schizophrenia: contributing factors and validated assessments. J. Clin. Psychiatry 75 Suppl 1, 15-20 (2014).
6. Kahn, R. S. & Keefe, R. S. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry 70, 1107-1112 (2013).
7. Lepage, M., Bodnar, M. & Bowie, C. R. Neurocognition: clinical and functional outcomes in schizophrenia. Can. J. Psychiatry 59, 5-12 (2014).
8. Mueller, D. R., Schmidt, S. J. & Roder, V. One-year randomized controlled trial and follow-up of integrated neurocognitive therapy for schizophrenia outpatients. Schizophr. Bull. 41, 604-616 (2015).
9. Bora, E. et al. Cognitive deficits in youth with familial and clinical high risk to psychosis: a systematic review and meta-analysis. Acta Psychiatr. Scand. 130, 1-15 (2014).
10. Addington, J. & Heinssen, R. Prediction and prevention of psychosis in youth at clinical high risk. Annu. Rev. Clin. Psychol. 8, 269-289 (2012).
11. Ising, H. K. et al. Cost-effectiveness of preventing first-episode psychosis in ultrahigh-risk subjects: multi-centre randomized controlled trial. Psychol. Med. 45, 1435-1446 (2015).
12. Preti, A. & Cella, M. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr. Res. 123, 30-36 (2010).
13. Bora, E. & Murray, R. M. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? Schizophr. Bull. 40, 744-755 (2014).
14. Lim, J. et al. Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis-Findings from the Longitudinal Youth at Risk Study (LYRIKS). Schizophr. Res. 164, 8-14 (2015).
15. Lin, A. et al. Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophr. Res. 132, 1-7 (2011).
16. Niendam, T. A. et al. The course of neurocognition and social functioning in individuals at ultra high risk for psychosis. Schizophr. Bull. 33, 772-781 (2007).
17. Arango, C., Fraguas, D. & Parellada, M. Differential neurodevelopmental trajectories in patients with early-onset bipolar and schizophrenia disorders. Schizophr. Bull. 40 Suppl 2, S138-S146 (2014).
18. Agnew-Blais, J. C. et al. Early childhood IQ trajectories in individuals later developing schizophrenia and affective psychoses in the new england family studies. Schizophr. Bull. 41, 817-823 (2015).
19. van Oel, C. J., Sitskoorn, M. M., Cremer, M. P. & Kahn, R. S. School performance as a premorbid marker for schizophrenia: a twin study. Schizophr. Bull. 28, 401-414 (2002).
20. Ullman, V. Z., Levine, S. Z., Reichenberg, A. & Rabinowitz, J. Real-world premorbid functioning in schizophrenia and affective disorders during the early teenage years: a population-based study of school grades and teacher ratings. Schizophr. Res. 136, 13-18 (2012).
21. Woodberry, K. A., Giuliano, A. J. & Seidman, L. J. Premorbid IQ in schizophrenia: a meta-analytic review. Am. J. Psychiatry 165, 579-587 (2008).
22. Meier, M. H. et al. Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study. Am. J. Psychiatry 171, 91-101 (2014).
23. Vorstman, J. A. et al. Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome. JAMA Psychiatry 72, 377-385 (2015).
24. Liu, C. H., Keshavan, M. S., Tronick, E. & Seidman, L. J. Perinatal risks and childhood premorbid indicators of later psychosis: next steps for early psychosocial interventions. Schizophr. Bull. 41, 801-816 (2015).
25. Seidman, L. J. & Nordentoft, M. New targets for prevention of schizophrenia: is it time for interventions in the premorbid phase? Schizophr. Bull. 41, 795-800 (2015).
26. Howes, O. D. & Kapur, S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 35, 549-562 (2009).
27. Kahn, R. S. & Sommer, I. E. The neurobiology and treatment of first-episode schizophrenia. Mol. Psychiatry 20, 84-97 (2014).
28. Schmidt, M. J. & Mirnics, K. Neurodevelopment, GABA system dysfunction, and schizophrenia. Neuropsychopharmacology 40, 190-206 (2015).
29. Pocklington, A. J. et al. Novel findings from CNVs implicate inhibitory and excitatory signaling complexes in schizophrenia. Neuron 86, 1203-1214 (2015).
30. Liu, Z., Neff, R. A. & Berg, D. K. Sequential interplay of nicotinic and GABAergic signaling guides neuronal development. Science 314, 1610-1613 (2006).
31. Tsai, G. E. & Lin, P. Y. Strategies to enhance N-methyl-D-aspartate receptormediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr. Pharm. Des. 16, 522-537 (2010).
32. van Berckel, B. N. et al. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology 21, 203-210 (1999).
33. Goff, D. C. et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56, 21-27 (1999).
34. Weiser, M. et al. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J. Clin. Psychiatry 73, e728-e734 (2012).
35. Kantrowitz, J. T. et al. High dose D-serine in the treatment of schizophrenia. Schizophr. Res. 121, 125-130 (2010).
36. Iwata, Y. et al. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Mol. Psychiatry 20, 1151-1160 (2015).
37. Nomura, J. et al. Role for neonatal D-serine signaling: prevention of physiological and behavioral deficits in adult Pick1 knockout mice. Mol. Psychiatry 21, 386-393 (2016).
38. Marx, C. E. et al. Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology (Berl) 231, 3647-3662 (2014).
39. Vinkers, C. H., Mirza, N. R., Olivier, B. & Kahn, R. S. The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline. Exp. Opin. Investig. Drugs 19, 1217-1233 (2010).
40. Rudolph, U. & Mohler, H. gabaa receptor subtypes: therapeutic potential in down syndrome, affective disorders, schizophrenia, and autism. Annu. Rev. Pharmacol. Toxicol. 54, 483-507 (2014).
41. Gill, K. M. & Grace, A. A. The role of alpha5 GABAA receptor agonists in the treatment of cognitive deficits in schizophrenia. Curr. Pharm. Des. 20, 5069-5076 (2014).
42. Buchanan, R. W. et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol. Psychiatry 69, 442-449 (2011).
43. Oberman, L. M., Pascual-Leone, A. & Rotenberg, A. Modulation of corticospinal excitability by transcranial magnetic stimulation in children and adolescents with autism spectrum disorder. Front. Hum. Neurosci. 8, 627 (2014).
44. Wang, D. D. & Kriegstein, A. R. Blocking early GABA depolarization with bumetanide results in permanent alterations in cortical circuits and sensorimotor gating deficits. Cereb Cortex 21, 574-587 (2011).
45. Bruining, H. et al. Paradoxical benzodiazepine response: a rationale for bumetanide in neurodevelopmental disorders? Pediatrics 136, e539-e543 (2015).
46. Meck, W. H. & Williams, C. L. Choline supplementation during prenatal development reduces proactive interference in spatial memory. Brain Res. Dev. Brain Res. 118, 51-59 (1999).
47. Ross, R. G. et al. Perinatal choline effects on neonatal pathophysiology related to later schizophrenia risk. Am. J. Psychiatry 170, 290-298 (2013).
48. Steullet, P. et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology? Schizophr. Res.; e-pub ahead of print (2014).
49. Miller, B. J., Culpepper, N. & Rapaport, M. H. C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin. Schizophr. Relat. Psychoses 7, 223-230 (2014).
50. Fineberg, A. M. & Ellman, L. M. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol. Psychiatry 73, 951-966 (2013).
51. Coughlin, J. M. et al. Marked reduction of soluble superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with recent-onset schizophrenia. Mol. Psychiatry 18, 10-11 (2013).
52. Bergink, V., Gibney, S. M. & Drexhage, H. A. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol. Psychiatry 75, 324-331 (2014).
53. Monin, A. et al. Glutathione deficit impairs myelin maturation: relevance for white matter integrity in schizophrenia patients. Mol. Psychiatry 20, 827-838 (2014).
54. Berk, M., Malhi, G. S., Gray, L. J. & Dean, O. M. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol. Sci. 34, 167-177 (2013).
55. Powell, S. B., Sejnowski, T. J. & Behrens, M. M. Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia. Neuropharmacology 62, 1322-1331 (2012).
56. Jiang, Z., Rompala, G. R., Zhang, S., Cowell, R. M. & Nakazawa, K. Social isolation exacerbates schizophrenia-like phenotypes via oxidative stress in cortical interneurons. Biol. Psychiatry 73, 1024-1034 (2013).
57. Cabungcal, J. H. et al. Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron 83, 1073-1084 (2014).
58. Hashimoto, K. Targeting of NMDA receptors in new treatments for schizophrenia. Exp. Opin. Ther. Targets 18, 1049-1063 (2014).
59. Giordano, E. & Visioli, F. Long-chain omega 3 fatty acids: molecular bases of potential antioxidant actions. Prostaglandins Leukot. Essent. Fatty Acids 90, 1-4 (2014).
60. Lorente-Cebrian, S. et al. An update on the role of omega-3 fatty acids on inflammatory and degenerative diseases. J. Physiol. Biochem. 71, 341-349 (2015).
61. Amminger, G. P., Schafer, M. R., Schlogelhofer, M., Klier, C. M. & McGorry, P. D. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat. Commun. 6, 7934 (2015).
62. Markulev, C. et al. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Early Interv. Psychiatry; e-pub ahead of print (2015).
63. Ryan, A. S. et al. Effects of long-chain polyunsaturated fatty acid supplementation on neurodevelopment in childhood: a review of human studies. Prostaglandins Leukot. Essent. Fatty Acids 82, 305-314 (2010).
64. Dalsgaard, S. et al. Association between Attention-Deficit Hyperactivity Disorder in childhood and schizophrenia later in adulthood. Eur. Psychiatry 29, 259-263 (2014).
65. Maibing, C. F. et al. Risk of schizophrenia increases after all child and adolescent psychiatric disorders: a nationwide study. Schizophr. Bull. 41, 963-970 (2014).
66. Keightley, P. C., Koloski, N. A. & Talley, N. J. Pathways in gut-brain communication: evidence for distinct gut-to-brain and brain-to-gut syndromes. Aust. NZ J. Psychiatry 49, 207-214 (2015).
67. Smythies, L. E. & Smythies, J. R. Microbiota, the immune system, black moods and the brain-melancholia updated. Front. Hum. Neurosci. 8, 720 (2014).
68. Tomasik, J., Yolken, R. H., Bahn, S. & Dickerson, F. B. Immunomodulatory effects of probiotic supplementation in schizophrenia patients: a randomized, placebocontrolled trial. Biomark Insights 10, 47-54 (2015).
69. Mohammadi, A. A. et al. The effects of probiotics on mental health and hypothalamic-pituitary-adrenal axis: a randomized, double-blind, placebo-controlled trial in petrochemical workers. Nutr. Neurosci.; e-pub ahead of print (2015).
70. Aas, M., Dazzan, P. et al. Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis. Psychol. Med. 41, 463-476 (2011).
71. Hempel, R. J. et al. Diurnal cortisol patterns of young male patients with schizophrenia. Psychiatry Clin. Neurosci. 64, 548-554 (2010).
72. Walder, D. J., Walker, E. F. & Lewine, R. J. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol. Psychiatry 48, 1121-1132 (2000).
73. Pruessner, M. et al. Attenuated cortisol response to acute psychosocial stress in individuals at ultra-high risk for psychosis. Schizophr. Res. 146, 79-86 (2013).
74. Walker, E. F. et al. Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. Biol. Psychiatry 74, 410-417 (2013).
75. Nordholm, D. et al. Pituitary gland volume in patients with schizophrenia, subjects at ultra high-risk of developing psychosis and healthy controls: a systematic review and meta-analysis. Psychoneuroendocrinology 38, 2394-2404 (2013).
76. Garcia-Bueno, B., Caso, J. R. & Leza, J. C. Stress as a neuroinflammatory condition in brain: damaging and protective mechanisms. Neurosci. Biobehav. Rev. 32, 1136-1151 (2008).
77. Vaessen, T., Hernaus, D., Myin-Germeys, I. & van Amelsvoort, T. The dopaminergic response to acute stress in health and psychopathology: a systematic review. Neurosci. Biobehav. Rev. 56, 241-251 (2015).
78. Schiavone, S., Jaquet, V., Trabace, L. & Krause, K. H. Severe life stress and oxidative stress in the brain: from animal models to human pathology. Antioxid. Redox Signal. 18, 1475-1490 (2013).
79. Hildebrandt, T. & Greif, R. Stress and addiction. Psychoneuroendocrinology 38, 1923-1927 (2013).
80. Manetti, L., Cavagnini, F., Martino, E. & Ambrogio, A. Effects of cocaine on the hypothalamic-pituitary-adrenal axis. J. Endocrinol. Invest. 37, 701-708 (2014).
81. Waasdorp, T. E., Bradshaw, C. P. & Leaf, P. J. The impact of schoolwide positive behavioral interventions and supports on bullying and peer rejection: a randomized controlled effectiveness trial. Arch. Pediatr. Adolesc. Med. 166, 149-156 (2012).
82. Cullen, A. E., Fisher, H. L., Roberts, R. E., Pariante, C. M. & Laurens, K. R. Daily stressors and negative life events in children at elevated risk of developing schizophrenia. Br. J. Psychiatry 204, 354-360 (2014).
83. van Dam, D. S. et al. Childhood bullying and the association with psychosis in non-clinical and clinical samples: a review and meta-analysis. Psychol. Med. 42, 2463-2474 (2012).
84. Stoltz, S. et al. Effectiveness of an individual school-based intervention for children with aggressive behaviour: a randomized controlled trial. Behav. Cogn. Psychother. 41, 525-548 (2013).
85. Lereya, S. T., Copeland, W. E., Costello, E. J. & Wolke, D. Adult mental health consequences of peer bullying and maltreatment in childhood: two cohorts in two countries. Lancet Psychiatry 2, 524-531 (2015).
86. Kelleher, I. et al. Childhood trauma and psychosis in a prospective cohort study: cause, effect, and directionality. Am. J. Psychiatry 170, 734-741 (2013).
87. Norberg, M. M., Kezelman, S. & Lim-Howe, N. Primary prevention of cannabis use: a systematic review of randomized controlled trials. PLoS ONE 8, e53187 (2013).
88. Patnode, C. D. et al. Primary care behavioral interventions to prevent or reduce illicit drug use and nonmedical pharmaceutical use in children and adolescents: a systematic evidence review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 160, 612-620 (2014).
89. Vogl, L. E., Newton, N. C., Champion, K. E. & Teesson, M. A universal harmminimisation approach to preventing psychostimulant and cannabis use in adolescents: a cluster randomised controlled trial. Subst. Abuse Treat. Prev. Policy 9, 24 (2014).
90. Deste, G. et al. Persistence of effectiveness of cognitive remediation interventions in schizophrenia: a 1-year follow-up study. Schizophr. Res. 161, 403-406 (2015).
91. Kontis, D., Huddy, V., Reeder, C., Landau, S. & Wykes, T. Effects of age and cognitive reserve on cognitive remediation therapy outcome in patients with schizophrenia. Am. J. Geriatr. Psychiatry 21, 218-230 (2013).
92. Bowie, C. R., Grossman, M., Gupta, M., Oyewumi, L. K. & Harvey, P. D. Cognitive remediation in schizophrenia: efficacy and effectiveness in patients with early versus long-term course of illness. Early Interv. Psychiatry 8, 32-38 (2014).
93. Vita, A. et al. Predictors of cognitive and functional improvement and normalization after cognitive remediation in patients with schizophrenia. Schizophr. Res. 150, 51-57 (2013).
94. Fisher, M., Loewy, R., Hardy, K., Schlosser, D. & Vinogradov, S. Cognitive interventions targeting brain plasticity in the prodromal and early phases of schizophrenia. Annu. Rev. Clin. Psychol. 9, 435-463 (2013).
95. Cotman, C. W. & Berchtold, N. C. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 25, 295-301 (2002).
96. Draganski, B. et al. Neuroplasticity: changes in grey matter induced by training. Nature 427, 311-312 (2004).
97. Douw, L., Nieboer, D., van Dijk, B. W., Stam, C. J. & Twisk, J. W. A healthy brain in a healthy body: brain network correlates of physical and mental fitness. PLoS ONE 9, e88202 (2014).
98. Lee, T. M. et al. Aerobic exercise interacts with neurotrophic factors to predict cognitive functioning in adolescents. Psychoneuroendocrinology 39, 214-224 (2014).
99. Gottesman, I. I. & Shields, J. A polygenic theory of schizophrenia. Proc. Natl Acad. Sci. USA 58, 199-205 (1967).
100. Rasic, D., Hajek, T., Alda, M. & Uher, R. Risk of mental illness in offspring of parents with schizophrenia, bipolar disorder, and major depressive disorder: a meta-analysis of family high-risk studies. Schizophr. Bull. 40, 28-38 (2014).
101. Bassett, A. S. et al. The schizophrenia phenotype in 22q11 deletion syndrome. Am. J. Psychiatry 160, 1580-1586 (2003).
102. Duijff, S. N. et al. Cognitive development in children with 22q11.2 deletion syndrome. Br. J. Psychiatry 200, 462-468 (2012).
103. Goodman, B. K., Rutberg, J., Lin, W. W., Pulver, A. E. & Thomas, G. H. Hyperprolinaemia in patients with deletion (22)(q11.2) syndrome. J. Inherit. Metab. Dis. 23, 847-848 (2000).
104. Crump, F. T., Fremeau, R. T. & Craig, A. M. Localization of the brain-specific high-affinity l-proline transporter in cultured hippocampal neurons: molecular heterogeneity of synaptic terminals. Mol. Cell. Neurosci. 13, 25-39 (1999).
105. Cohen, S. M. & Nadler, J. V. Proline-induced potentiation of glutamate transmission. Brain Res. 761, 271-282 (1997).
106. Raux, G. et al. Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome. Hum. Mol. Genet. 16, 83-91 (2007).
107. Vorstman, J. A. et al. Proline affects brain function in 22q11DS children with the low activity COMT 158 allele. Neuropsychopharmacology 34, 739-746 (2009).
108. Rees, E. et al. Analysis of copy number variations at 15 schizophrenia associated loci. Br. J. Psychiatry. 204, 108-114 (2014).
109. Vorstman, J. A. & Ophoff, R. A. Genetic causes of developmental disorders. Curr. Opin. Neurol. 26, 128-136 (2013).
110. Laurens, K. R., Hobbs, M. J., Sunderland, M., Green, M. J. & Mould, G. L. Psychoticlike experiences in a community sample of 8000 children aged 9 to 11 years: an item response theory analysis. Psychol. Med. 42, 1495-1506 (2012).
111. Poulton, R. et al. Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch. Gen. Psychiatry 57, 1053-1058 (2000).
112. Fisher, H. L. et al. Specificity of childhood psychotic symptoms for predicting schizophrenia by 38 years of age: a birth cohort study. Psychol. Med. 43, 2077-2086 (2013).
113. Mittal, V. A., Dean, D. J., Mittal, J. & Saks, E. R. Ethical, legal, and clinical considerations when disclosing a high-risk syndrome for psychosis. Bioethics 29, 543-556 (2015).
114. Appelbaum, P. S. Ethical challenges in the primary prevention of schizophrenia. Schizophr. Bull. 41, 773-775 (2015).
115. Fineberg, N. A. et al. The size, burden and cost of disorders of the brain in the UK. J. Psychopharmacol. 27, 761-770 (2013).
116. Agnew-Blais, J. C. et al. Early childhood IQ trajectories in individuals later developing schizophrenia and affective psychoses in the new england family studies. Schizophr. Bull. 41, 817-823 (2015).
117. Cannon, T. D. et al. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol. Psychiatry 77, 147-157 (2015).
118. Nieman, D. H. et al. Psychosis prediction: stratification of risk estimation with information-processing and premorbid functioning variables. Schizophr. Bull. 40, 1482-1490 (2014).
119. Gale, C. R. et al. Cognitive ability in early adulthood and risk of 5 specific psychiatric disorders in middle age: the Vietnam experience study. Arch. Gen. Psychiatry 65, 1410-1418 (2008).